UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) December 1, 2006

DADE BEHRING HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-50010	36-3989270
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

1717 Deerfield Road, Deerfield, Illinois		60015
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (847) 267-5300

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Attached hereto as Exhibit 99.1 is a press release dated December 1, 2006 describing certain changes to the company officerships. The information contained in this report, including the exhibit attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 Dade Behring Holdings, Inc. Press Release dated December 1, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		DADE BEHRING HOLDINGS, INC.


December 1, 2006	By:	/s/ JOHN M. DUFFEY
		John M. Duffey
		Chief Financial Officer

EXHIBIT INDEX

Exhibits:
Exhibit 99.1		Press release dated December 1, 2006.

Exhibit 99.1

DADE BEHRING INC.		Tel: +1 (847) 267-5300
1717 Deerfield Road		Fax: +1 (847) 267-1699
P.O. Box 778
Deerfield, IL 60015-0778

Contact:

Nancy Krejsa

(847) 267-5483

DADE BEHRING NAMES DONAL QUINN CHIEF OPERATING OFFICER
AND MARK WOLSEY-PAIGE CHIEF STRATEGY AND TECHNOLOGY OFFICER

Deerfield, IL (December 1, 2006) — Dade Behring Holdings, Inc. (NASDAQ:DADE), the world’s largest company solely dedicated to clinical diagnostics, announced today the appointment of Donal Quinn to the newly created position of Chief Operating Officer, and also announced the appointment of Mark Wolsey-Paige to the newly created position of Chief Strategy and Technology Officer, both reporting to Jim Reid-Anderson, Chairman, President and CEO. Hiroshi Uchida, President, Global Operations and Supply Chain has resigned from the company to join another firm.

“Both Donal and Mark bring extensive capabilities and industry expertise to these two new important roles,” said Jim Reid-Anderson, Chairman, President and CEO, Dade Behring Inc. “I am confident Donal’s and Mark’s leadership and commitment will further strengthen Dade Behring’s ability to provide differentiated products and services to our clinical laboratory customers.”

Donal Quinn joined Dade Behring in 1998 and has served as the company’s President, Global Customer Management since 2002, responsible for global sales, service and marketing. As Chief Operating Officer, in addition to his current responsibilities, Mr. Quinn will also oversee global reagent and consumable manufacturing and global logistics.

For the last four years, Mark Wolsey-Paige has managed the company’s research and development and strategic planning functions, and in his new role as Chief Strategy and Technology Officer, he will also assume responsibility for instrument manufacturing and the company’s global supply chain. Mr. Wolsey-Paige joined Baxter Diagnostics, the company’s predecessor, in 1991. Both Messrs. Quinn’s and Wolsey-Paige’s newly appointed roles will become effective January 1, 2007.

About Dade Behring

With 2005 revenue of nearly $1.7 billion, Dade Behring is the world’s largest company solely dedicated to clinical diagnostics. It offers a wide range of products, systems and services designed to meet the day-to-day needs of laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at www.dadebehring.com.

# # #